SEC Comment Letter 0000000000-26-005217 to COMPUGEN LTD (CGEN)
COMPUGEN LTD
Date: May 21, 2026 · CIK: 0001119774 · Accession: 0000000000-26-005217
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-295989
Letter
May 21, 2026 Eran Ophir, Ph.D. Chief Executive Officer Compugen Ltd. Azrieli Center 26 Harokmim Street Building D Holon 5885849, Israel Re: Compugen Ltd. Registration Statement on Form F-3 Filed May 18, 2026 File No. 333-295989 Dear Eran Ophir Ph.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Daniel I. Goldberg, Esq.
Show Raw Text
May 21, 2026 Eran Ophir, Ph.D. Chief Executive Officer Compugen Ltd. Azrieli Center 26 Harokmim Street Building D Holon 5885849, Israel Re: Compugen Ltd. Registration Statement on Form F-3 Filed May 18, 2026 File No. 333-295989 Dear Eran Ophir Ph.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Daniel I. Goldberg, Esq.